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Abstract
Diabetes is one of the most common metabolic diseases. Aside from the genetic factor, previous studies stated that other
factors such as environment, lifestyle, and paternal–maternal condition play critical roles in diabetes through DNA
methylation in specific areas of the genome. One of diabetic cases is caused by insulin resistance and changing the
homeostasis of blood glucose control so glucose concentration stood beyond normal rate (hyperglycemia). High fat diet has
been frequently studied and linked to triggering diabetes. However, most Asians consume rice (or food with high
carbohydrate) and food with monosodium glutamate (MSG). This habit could lead to pathophysiology of type 2 diabetes
mellitus (T2D). Previous studies showed that high-carbohydrate or high-MSG diet could change gene expression or modify
protein activity in body metabolism. This imbalanced metabolism can lead to pleiotropic effects of diabetes mellitus. In this
study, the authors have attempted to relate various changes in genes expression or protein activity to the high-carbohydrate
and high-MSG-induced diabetes. The authors have also tried to relate several genes that contribute to pathophysiology of
T2D and proposed several ideas of genes as markers and target for curing people with T2D. These are done by investigating
altered activities of various genes that cause or are caused by diabetes. These genes are selected based on their roles in
pathophysiology of T2D.
Keywords High carbohydrate ● Insulin resistance ● Monosodium glutamate ● Obesity ● Type 2 diabetes mellitus
Abbreviations
GLUT4 Glucose transporter 4
PDX1 Pancreatic and duodenal homeobox 1
NKX6.1 NK6 homeobox 1
MAFA MAF bZIPtranscritpion factor A
FOXO1 Forkhead box protein O1
GRP-78 Binding immunoglobulin protein
PERK Protein kinase R (PKR)-like endoplasmic
reticulum kinase
IRE1α Inositol-requiring enzyme 1 α
XBP1 X-box binding protein 1
CHOP C/EBP homologous protein
INSIG1 Insulin induced gene 1
SREBP-1c Sterol regulatory element binding protein 1c
SIRT1 NAD-dependent deacetylase sirtuin-1
SCD1 Stearoyl-CoA desaturase-1
PPAR Peroxisome proliferator-activated receptor
ATF4 Activating transcription factor 4
CREB-2 cAMP-response element binding protein 2
MEG3 Maternally expressed 3
SLC2A4 Solute carrier family 2 member 4
H3K9me3 Trimethylation of lysine 9 on histone H3 protein
PCK1 Phosphoenolpyruvate carboxykinase 1 (soluble)
ACO Acyl-CoA oxidase
CPT1 Carnitine palmitoyltransferase 1
BIFEZ Bifunctionalenzyme
ANGPTL4 Angiopoietin-like 4
PDK4 Pyruvate dehydrogenase lipoamide kinase
isozyme 4
TIF2 Transcriptional mediators/intermediary factor 2
UCP3 Mitochondrial uncoupling protein 3
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PGC-1α Peroxisome proliferator-activated receptor
gamma co-activator 1-alpha
SRC 1 Steroid Receptor Co-activator 1
aP2 Adipocyte Protein 2
SHP Small Heterodimer Partner
MSG Monosodium Glutamate
Introduction
Diabetic prevalences are continuously increasing and they
were predicted to reach 693 million in 2045 [1]. Various
factors contributed to the emergence of diabetes ranging
from parental genetics [2], maternal epigenetic inheritance
due to nutritional imbalances consumption during preg-
nancy [3], lifestyle, and diet [4, 5]. Physiologically, diabetes
could be due to insulin resistance [6], insulin secretory
dysfunction [7], or death of pancreas β-cell [8]. The
pathogenesis of type 2 diabetes mellitus (T2D) related to
obesity has been well reviewed [6]. Epidemic and epige-
netics that convey relationship between genetics and
environment are closely related to T2D cases [9, 10]. The
fact that famines impact on the family health, pregnancy
planning, lifestyle, and diet in early stages of pregnancy
contributed to future risks of various metabolic disorders,
such as obesity and diabetes. This fact has been well-
reviewed in the literature [9]. Various environmental factors
previously mentioned lead to various epigenetic modifica-
tions and cause early insulin resistance associated with the
fetal low birth weight [10].
Certain patterns of diets increase the chances of T2D due
to alteration in the gene expression. High-fat diet is the most
commonly studied and frequently used to induce diabetes
[11, 12]. High-fat diets internalize and reduce the expres-
sion of pancreatic glucose transporter gene (GLUT2) and
glucokinase caused by the hyperglycemia and create a
vicious loop of impaired insulin secretion [13, 14]. This
diet also reduces the expression of GLUT4 protein and
causes insulin resistance in skeletal muscles. High-fat diets
also inactivated insulin receptor substrate (IRS-1) in liver
and caused inflammation in mice models [15]. Methylation
studies on PDK4 also revealed that high-fat-diet-induced
methylation on a specific CpG site before the onset of
hyperglycemia as one proof of epigenetic regulation plays
an important role in metabolic disorder [16].
Primary food with high glycemic index, such as rice, is a
staple food for more than half of the world’s population in
various Asian countries [17]. High carbohydrate diet, such
as refined grain is also associated with an increased risk of
T2D [18–20]. High sucrose and fructose diets are also
contributing factors to T2D since sucrose and fructose cause
pancreas and liver toxicity [21‒23]. Another relevant Asian
food additive that can induce T2D is the high intake of
MSG [24‒28]. Epigenetically, a newborn female in the
suckling period who eats a high-carbohydrate diet has been
reported to readily develop hyperinsulinemia and to acquire
obesity in the adulthood [29]. The second generation of
these female rats spontaneously develop the similar phe-
notype even without any intervention studies indicating
maternal fetal programming [29]. MSG-induced obesity by
subcutaneous injection of female Wistar rats’ parent, has
been reported to bring forth male offspring that experienced
various metabolic disorders, such as insulin and leptin
resistance [30]. These initial facts implied that both high-
carbohydrate and high-MSG diets contribute to the emer-
gence of T2D.
To the extent of the authors’ literature reviews, diets with
high carbohydrate and high MSG have not been so exten-
sively reviewed as those with high fat (especially in the
consequences of high-carbohydrate and high-MSG intakes
on gene expression). This review focuses on exploring the
genetic interactions of both diet patterns that leads to T2D.
Literature reviews related to T2D and human central
metabolism were employed to initially screen some genes or
proteins that have been extensively studied. Then, the
possibilities of alteration of these genetic expressions using
carbohydrate and MSG adjustment were also investigated.
Thus, this review can provide insights into the screening
processes of genes that can serve as potential biomarkers in
T2D prediction. The genes or the proteins can also offer
possible breakthroughs in therapies for T2D patients.
Genetic aspects that promote T2D: high-
carbohydrate diet study
High-carbohydrate feeding after a period of time of non-
carbohydrate diets caused the mice to enter fast hypergly-
cemic period [13]. The high-carbohydrate diet in mice
models dephosphorylate FoxO1 without reducing its
expression where the phosphorylation was regulated in Akt
pathway. Thus, FoxO1 stayed in the nucleus and sig-
nificantly reduced the expression of PDX1, NKX6.1, and
MAFA genes that are essential for the survival and the
maintenance of β-pancreas cell and insulin production
[13, 31, 32]. High-fructose diets were also found to increase
both the m-RNA content of FoxO1 and the expression of
pancreatic GRP-78, PERK, IRE1α, XBP1, CHOP gene,
hepatic GRP-78, and caspase activity [21]. All these genes
belong to the family of endoplasmic reticulum stress mar-
kers and relate to cell death. Interestingly, high fructose
diets also reduce the expression of INSIG1 [21]. This is the
protein that regulates SREBP-1c that is important to syn-
thesize fat when the cells are rich in carbohydrate [33].
In contrast, activation and retainment of FoxO1 in the
nucleus by deacetylation are essential to protect β-pancreas
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cell of diabetic mice within the long term by reducing the
dependence on fatty acid oxidation as energy source [34].
This signifies that FoxO1 activation might be one approach
of our body to control homeostasis.
Animal models showed that high-carbohydrate diet
induced the expression of hepatic acetyl-CoA carboxylase
stearoyl-CoA desaturase 1 gene (Scd1), while Scd1 nor-
mally is not expressed in liver but expressed constitutively
in adipose tissue [35‒38]. High-carbohydrate diet was
found to increase the expression of various elongase and
desaturase enzymes that synthesize unsaturated fatty acid,
especially monounsaturated fatty acid in liver [39]. Scd1
activation created vicious cycle which created insulin
resistance. Downregulation of Scd1 proved to increase the
phosphorylation of AKT and to alleviate the insulin resis-
tance [40‒43].
Although Scd1 might be an interesting gene to be
downregulated, Scd1 deficiency alone was found to be
insufficient to protect mice from getting obese [44]. In
contrast, the activation of Scd1 gene specifically in skeletal
muscle enhanced the activation of PPAR-δ to oxidize fat
and increased the metabolism in skeletal muscles that could
protect T2D mice from obesity [45]. This opposing phe-
notype in skeletal muscles and hepatic cells both arising
from the activation of Scd1 expression denoted that each
protein behaves differently and possibly targets different
proteins in each organ. The Scd1 gene correlation with
high-carbohydrate diet has been investigated for more than
two decades but with no firm consequences. Care must be
taken when making a research to silence this gene or to
make an inhibitor for Scd1. Clearly, more data are needed to
be able to map the effect of Scd1 on not only various genes
but also various organs.
ATF4 (or CREB2) deficiency has been shown to suppress
the expression of SCD1 in liver, and ATF4-deficiency mice
has lower fat content compared with the normal genotype.
In high-carbohydrate diet mice, deletion of ATF4 improved
insulin sensitivity and caused hypoglycemia [46, 47]. ATF4
deletion also significantly reduced the expression of hepatic
PPAR-γ which contributed to lipogenesis resulting in
reduction of other genes expression involved in lipogenesis,
such as SREBP-1c and acetyl-coA carboxylase. ATF4
deletion also protected high-fructose diet mice from devel-
oping hypertriglyceridemia and liver steatosis [48]. This
fact was further enhanced by the downregulation of ATF4 in
liver by miRNA-214 that could alleviate gluconeogenesis
and reduce the expression of FoxO1 in high-fat diet mice
[49]. MEG3, a noncoding RNA, was found to be a com-
peting endogenous RNA for miRNA-214 that resulted in
increase of ATF4 and FoxO1 expressions that create insulin
resistance [50]. These facts might seem that downregulating
ATF4 or regulating the miRNA-214-MEG3 axis can be a
promising way to combat T2D. Nevertheless, referring to
the contrasting long-term effect of FoxO1 [34], more data
are required to observe long-term effects of ATF4 up- or
downregulation on the diabetic animal models.
Evenly, nutritional factors of high-carbohydrate and
high-fat diet-induced diabetic mice overlap with each other
in the genetic pathways when a different metabolic pathway
is used. This condition possibly occurs when food enters the
body and several mechanisms of metabolisms interact with
each other to form a complex mechanism to maintain
homeostasis. Prolonged imbalanced diet or excessive car-
bohydrate consumption may lead to pathophysiology of
T2D. The idea of some gene expression and protein activity
alterations when the body encounters high-carbohydrate
diet is summarized in the following Figs. 1 and 2.
Genetic aspects that promote T2D: high-
MSG intervention study
Monosodium glutamate (MSG) has been linked with var-
ious metabolic disorders. Metabolism of MSG by dietary
intake is well reviewed [51]. Glutamate is a nonessential
amino acid that is usually oxidized or acted as precursor for
other amino acids in gut. With excess of MSG intakes, the
intestine capacity to absorb MSG remain unchanged. In
neonatal primate, high dose of MSG administered by gastric
tube, induced elevation of glutamate, and aspartate content
(the result of glutamate metabolism by liver) after 1 or 2 h
of treatment without any lesion in neuron [52]. Thus, MSG
is considered as GRAS food additive.
Here, the focus of the study is the genetical and experi-
mental effects of MSG intervention study toward expression
of genes and metabolism. However, it should be taken into
account that various experimental data used MSG injection
to develop obesity and hyperglycemic animal models to
reveal the genetic architecture between MSG and T2D.
MSG is also now a suspected obesogen—a small chemical
that could disrupt fat metabolism and appetite [53]. MSG
was found to impair glucagon-like peptide (GLP-1) secre-
tion in cell model, a peptide hormone that is important for
β-cell growth, and insulin production [54]. In short term
(3 h), secretion of GLP-1 was increased, but in chronic term
(72 h), cytotoxicity was observed and there was a reduction
in GLP-1 secretion [55].
MSG-induced hyperglycemia caused the same insulin
resistance phenomenon induced by streptozotocin. MSG
also caused obesity in the nongenetic mice models. How-
ever, MSG-induced diabetic mice did not experience an
increase in expression of TNF-α, a marker that is usually
used to indicate obesity and might also cause diabetes
[56, 57]. No reduction of pancreaticβ-cell in the MSG-
induced diabetes was observed compared with that in the
streptozotocin-induced diabetes [25].
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MSG-induced diabetic mice exerted decreased content of
GLUT4 protein (not GLUT1), disrupt glucose utilization,
and caused insulin resistance [58]. This is due to methyla-
tion of Slc2a4 promoter area that produced GLUT4 by
H3K9me3 using gastrocnemius skeletal cell [59]. An
increase of Slc2a2 gene expression (encoding GLUT2) and
pck1 (encoding key enzyme in gluconeogenesis in the liver)
was also induced in MSG-diabetic mice. This increase
caused glucose outflow and created hyperglycemia [60].
MSG-induced diabetes also takes a longer time to
develop hyperglycemia phenomenon, and the obesity per-
iod is usually the first indicator [26, 61–63]. Subcutaneous
injection of rats with MSG reduced the expression of genes
related to the fat oxidation, such as PPARα, ACO, CPT1,
and BIFEZ [64, 65]. Conversely, MSG-induced diabetic
mice in neonatal period gain an increase of expression in
PPARα and PPARγ, and inflammation [66]. Although both
mechanisms are intertwined, MSG observably induced the
lipogenesis. Chiglitazar, the agonist PPARα and PPARγ, is
reported to inhibit the phosphorylation of PPARγ, thus
deactivates the protein and increases the expression of
ANGPTL4 and PDK4 [67‒69]. ANGPTL4 is a protein that
protects human from getting obese and myocardial infarc-
tion due to high-fat diet by inhibiting the lipoprotein lipase
activity, reducing free fatty acid levels in serum [70]. PDK4
is an enzyme that turns off the pyruvate dehydrogenase and
in turn, activates the β-oxidation pathway that is often
expressed in skeletal muscle cell, and can be repressed by
insulin. An increase of PDK4 expression is often observed
in diabetic patients and increases insulin resistance and
dependence on fatty acids oxidation as energy source
[71, 72]. However, in a short-term high-fat diet, the increase
of PDK4 expression is important to balance the glucose and
fat level. The increase of ANGPTL4 and PDK4 expression
is regarded as the feedback mechanism to protect cells from
fatty acid-induced oxidative stress [73, 74].
The loss-of-function experiment using skeletal muscle
cells and adipocytes on TIF2 revealed PPARγ expression
reduction [75]. The deletion of TIF2 reduced the expression
of lipoprotein lipase, aP2, and increased lipolysis and the
resistance of MSG-diabetic induced mice from getting
obese in combination with SRC1 expression for better
energy expenditure [75]. Experiment on TIF2−/− mouse
supported the idea about the role of TIF2 on obesity
whereas TIF2 and SRC1 act antagonistically toward UCP3
expression [76]. Silencing TIF2 gene increased the
expression of UCP3 and in turn, increased body
Fig. 2 Changes of gene expression by MSG-induced diabetes in
neonatal period
Fig. 1 Mechanism of high-
carbohydrate and high-fructose
diets affecting gene expression
and protein activity
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metabolism, and reduced weight gain [77]. Loss-of-function
of TIF2 also induced the expression of PGC-1α in skeletal
muscle cells, and the expression increased the oxidative
metabolism of muscle cell [76, 78]. SRC3 deletion on mice
also increased the PGC-1α activity by reducing acetylation
on skeletal muscle cells [79]. However, expressed PGC-1α
raised different phenotypes from different organs and peri-
ods of induction. Pancreatic overexpression of PGC-1α in
neonatal period inhibited the expression of PDX1. The
inhibition of PDX1 expression caused dysfunction and mass
reduction in pancreatic β-cell. However, PGC-1α over-
expression in the adult mice did not affect the
pancreaticβ-cell [80].
Recently, SIRT1, a histone deacetylase protein, has
been proved to increase insulin sensitivity. SIRT1
expression improved glycemic control and insulin sensi-
tivity on liver, muscle, adipose tissue, and β-cell pancreas
[81, 82]. It is further supported by mice that are deficient
in SIRT1 which develop hyperglycemic and insulin
resistance [83]. MSG-induced diabetic mice does not
seem to cause any changes in SIRT1 expression level.
However, various ligands that acted as SIRT1 activator
such as resveratrol, SRT1720, and MHY2233, improved
the steatosis condition [60, 84, 85]. In contrast, genetic
diabetic db/db mice reportedly were in use [86]. Although
the activation of SIRT1 did stimulate the pancreatic β-cell
plasma insulin concentration, SIRT1 activation caused a
reduction in body temperature and metabolism (torpor
condition) with more long-term effects of weight gain and
hepatic steatosis [86].
However, acute knockout of SIRT1 lead to reduction of
hyperglycemia setting and an increase of insulin sensitivity
by increasing the liver responsiveness to insulin and redu-
cing gluconeogenesis [87, 88]. The results regarding SIRT1
effects on gluconeogenesis and insulin sensitivity seem
inconsistent. This discrepancy could be due to the feedback
mechanism on the SIRT1-FOXO1 pathway by SHP (enco-
ded by Nr0b2) [89]. Furthermore, SIRT1 knockout in
healthy mice brings normal fed and fasting blood glucose
level [89]. However, SIRT1 knockout in genetic diabetic
mice (double knockout on IRS1/2) resulted in better blood
glucose level and glucose tolerance, although the mice were
still insulin resistant. This implied that SIRT1 activation can
be completed in genetically derived diabetic patients or in
already diabetic patients. SIRT1 treatment might not be used
to prevent people from diabetes.
In general, MSG-induced mice are more related to obese
phenomenon. Quite a few involved genes are intertwined
with obesity, such as fat metabolism from PPARs family.
While high-carbohydrate-induced diabetes can also cause
lipogenesis by balancing the excess of carbohydrate into fat,
MSG-induced diabetes seems to directly activate lipogenesis.
The changes in genes expression triggered by MSG- induced
T2D are summarized in Fig. 3.
Involvement of genes and proteins in T2D
It is important to figure out whether the disruption of the gene
expression is the reason for the T2D, or whether the dis-
ruption is generated by the T2D. Two categories were used to
sort some genes whether the genes induce T2D, or T2D
changes the genes expression (Table 1). The genes that could
affect T2D development might be used as diabetes markers
and targeted to prevent T2D. While some gene expressions
that are altered after T2D has occurred can be treated to
alleviate the diabetes symptoms. The delicate interaction of
the proteins, such as pleiotropic effects and highly branched
signaling pathways and feedback mechanisms, also compli-
cates the treatment of the targeted gene without disrupting the
homeostasis of our body. Genes or proteins whose activities
are altered after diabetes and increase diabetes severity, or the
further missing link that still has to be developed is placed in
not determined (ND).
Various genes such as FOXO1, PDX1, ATF4, and INSIG1
proved to be important for the development of β-pancreas
cells, or to maintain the balance of metabolism to increase
glucose tolerance. Meanwhile, genes expression alteration
that directly corelate with carbohydrate or fat metabolism,
such as GLUT families, pck1, scd1, and PPAR are more
likely caused by feedback mechanism and complex regula-
tion to give better glucose level performa [60, 97]. Dis-
turbance of expression in genes like ACO, CPT1, TIF2,
SRC1, scd1, and UCP3 in muscle cells and adipocyte cells
are more into causing obesity, in which these genes are
related to fat metabolism and energy expenditure. Caution
must be taken that diabetes could also abberated these genes
expression directly related to metabolism and disruption of
these genes in early stage of development could also cause
various physiological imbalances. However, genes like TIF2,
SRC1, and PGC-1α were predicted to be more upstream in
the signaling pathway. Thus, modulation of these genes
might prevent further physiological abberations related to
metabolism imbalances such as obesity and diabetes. SIRT1
expression was not changed by diabetes and its knockout
also did not cause T2D. SIRT1 is a promising gene to be
targeted in the already diabetic patient as previously stated
above. We further hypothesized that based on the animal
studies, both high carbohydrate (found in high glycemic
index food or energy-dense food) and introduction of high
MSG (by injection) might reinforce each other to increase the
prevalence of T2D or other metabolic disorders. The possi-
bility of intervention study employing both factors might be
noteworthy to be investigated.
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Population-based studies of high-
carbohydrate and high-MSG diet
Using animal and cell line models, high-MSG and high-
carbohydrate diets correlated and might also contribute to
the onset of T2D by disrupting expression and the activity
of various genes mentioned in Table 1. However, studies on
epidemiology might support or contrast the idea of the
correlation between T2D and high-MSG or high-
carbohydrate diet. Various factors contributed to this con-
ditions such as age, ethnicity, genetics, anatomical and
metabolic differences, or socioeconomics or even in the
experimental design itself [100].
Population study of dietary carbohydrate intake above
normal level in Japanese population showed that obese
participants develops T2D more readily than nonobese
participants. This indicated that large samples, genetic
effects, participants’ backgrounds should be considered in
the epidemiology study [101]. However, epidemiological
studies in China, India, United States, and UAE supported
the dietary style of high-carbohydrate intake (such as
refined grain and added sugar) positively correlated with
T2D [18, 102‒105]. Another profound study on epide-
miology related to the increasing risk of T2D was con-
ducted on sugar-sweetened diet beverages in female US
nurses in 1989 [106]. The intake of these high-calorie
beverages (such as, soft drink and fruit punch) was said to
be associated with the increasing chances of T2D devel-
opment. More than 60% diabetic people live in China and
India, followed by Japan [103, 107]. Asian countries, such
as China, India, or UAE are predicted to yield a higher rate
of diabetic prevalence [18, 102‒105]. Although general
Fig. 3 Mechanisms of changing
genes expression affected by
MSG-induced diabetes and of
genes affecting MSG-induced
diabetes
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population in Japan consume white rice and MSG-enriched
food like people in other Asian countries, uniquely, Japan is
projected to have only a small increase in the ratio of its
diabetic people in 2025. This fact might be due to the
nationwide health guidance and lifestyle intervention pro-
gram [107‒109].
Table 1 Summary of genes involved in diet-induced diabetes
Diet Gene/protein Effect Condition Reference
Changed by T2D Affecting T2D
development
ND
High carbohydrate FoxO1 [protein] Dephosphorylated ✓ [13]
Scd1 [gene] Increase of expression ✓ [36]
ATF4 [gene] Increase of expression ✓ [48]
INSIG1 [gene] Reduction of expression ✓ [90]
FoxO1 [gene] Increase of expression ✓ [90]
High-MSG GLUT4 [protein] Reduction of expression accompanied with whole-
body insulin resistance and increased plasma
concentration of inflammatory markers
✓ [91]
slc2a4 [gene] Reduction of expression that contributes to the
impairment of glycemic homeostasis
✓ [92]
Slc2a2 [gene] Increase of the content and collaboration with
nonalcoholic steatohepatitis to facilitate the glucose
input to hepatocyte
✓ [93]
pck1 [gene] Increase of expression level ✓ [94, 95]
PPARα and
PPARγ [protein]
Increase of the level and creation of inflammatory
effect(s)
✓ [66]
ACO [protein] Lowered expression might cause obesity ✓ [96]
CPT1 [gene] Increase of expression level possibly leading to
obesity
✓ [97]
PDK4 [gene] Increase of muscle PDK4 expression ✓ [98]
TIF2 [gene] Deletion of this gene protects mice from obese ✓ [75]
SRC1 [gene] Antagonist of TIF2− ✓ [76]
PGC-1α Activation at neonatal period reduced PDX1
expression and pancreas maturation
✓ [99]
SIRT1 [gene] Increase of this gene expression alleviates symptoms
in the already diabetic patient
✓ [81]
slc2a4 [gene] Reduction of expression that contributes to the
impairment of glycemic homeostasis
✓ [92]
Slc2a2 [gene] Increase of the content and collaboration with
nonalcoholic steatohepatitis to facilitate the glucose
input to hepatocyte
✓ [93]
pck1 [gene] Increase of expression level ✓ [94, 95]
PPARα and
PPARγ [protein]
Increase of the level and creation of inflammatory
effect(s)
✓ [66]
ACO [protein] Lowered expression might cause obesity ✓ [96]
CPT1 [gene] Increase of expression level possibly leading to
obesity
✓ [97]
PDK4 [gene] Increase of muscle PDK4 expression ✓ [98]
TIF2 [gene] Deletion of this gene protects mice from
getting obese
✓ [75]
SRC1 [gene] Antagonist of TIF2− ✓ [76]
PGC-1α Activation at neonatal period reduces PDX1
expression and pancreas maturation
✓ [99]
SIRT1 [gene] Increase of this gene expression alleviates symptoms
in the already diabetic patient
✓ [81]
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While studies on epidemiology related to high-
carbohydrate diet related to the risk of T2D development
are clearly [18, 102‒105], findings about human population
study at risk of high-MSG diet are inconsistent. Studies on
MSG-related diabetic cases have been frequently reported
using animal models. There is a lack of epidemiological data
of MSG consumption which contribute to T2D in comparison
to those of high-carbohydrate consumption. Epidemiology in
Spanish population has been linked to the increasing risks of
getting T2D to cardiovascular diseases due to high glutamate
plasma level [110]. Based on another epidemiology in
Thailand, daily consumption exceeding 5 g of MSG is con-
sidered risky to carry metabolic disorders, including T2D
[111]. MSG intakes have also been reported to increase the
incidence of overweight [112]. However, two studies from
the Jiangsu Nutrition Study argued that MSG intake did not
correlate with obesity, and even high MSG intake was
negatively associated with hyperglycemia [113, 114].
One possible explanation that could explain the opposing
results among the studies of epidemiology is the unready
transportation from the intestine into the blood circulation in
contrast to various experimental data that used MSG-
induced diabetic mice models by MSG subcutaneous
injection [51, 115]. Another explanation arises from
experimental data where life period is an important factor
related to the genetic programming by environmental fac-
tors. Mice at the age of 4 months old with high-MSG diet
are prone to various metabolic disorders, including the
increased signs of glucose intolerance. However, along with
the aging process, the impairment of metabolism from the
obesity effects can be attenuated [116].
By considering both experimental data from animal or cell
culture studies with epidemiological data, we summarize that
high-carbohydrate diet evidently positively correlates with
T2D and could cause the onset of T2D. Although MSG
studies are still in conflict with one another, we do not
encourage people to slacken their diets by consuming high
amount of MSG based on the experimental data of MSG
potentials to alter homeostasis on carbohydrate and fat
metabolism. All in all, lifestyle intervention shows to be a
promising primary prevention of diabetes, and healthy life-
style is shown to be comparable with metformin intake as
reported by Indian Diabetes Prevention Program [104].
Govermental policies can play a huge role on combating the
increasing prevalence of diabetes by encouraging a healthy
diet and lifestyle, such as taxation program in Thailand for
beverages which contain high level of sugar content [117].
Conclusion and future perspectives
High-fat diet is commonly known to induce T2D, espe-
cially in the case of high-carbohydrate and high-MSG
diets. However, high-MSG diet requires longer time to
develop hyperglycemia preceded by obesity. Various
genes, especially genes related to glucose and fat meta-
bolism are interrelated within these two diets. Branched
signal transduction pathways and different phenotypes of
each gene in different organs or ages revealed complicated
mechanisms that should be taken as precautions as the
targeted gene of interest to treat T2D or to construct a
specific biomarker for T2D. Initially, some activated or
repressed genes are only a feedback mechanism to control
body homeostasis related to the imbalanced diet. For
example, high-carbohydrate diet increased SCD-1
expression. Prolonged feedback mechanism often creates
vicious cycle thus developing metabolic syndromes
including obesity and T2D.
Increasing FoxO1 and ATF4 expressions or their
activation in high-carbohydrate-induced diabetic mice
will lead to insulin resistance. It could be interesting to
study the repression or the side effects of both genes of
diabetic mice for long-term experiments. Both genes
might have potential uses as a biomarker for early
detection of the T2D. The fact of MSG-induced diabetic
mice often leads to the increase of gene expressions
related to lipogenesis, such as PPARs family. However,
the changes in PPARs expression and activation may
disrupt the balance between glucose and lipid metabo-
lism. Both TIF2 and SIRT1 are promising genes in
alleviating insulin resistance developed from MSG-
induced diabetes. However, these strategies have also
exhibited some drawbacks. TIF2 silencing increased the
expression of PGC-1α that inhibited the maturation of
pancreas at neonatal period. Further information on TIF2
silencing of pancreatic cells from various ages of mice
models may enlighten the benefits of targeting TIF2 as a
gene of interest to treating T2D. It is still unclear how the
MSG affects the TIF2 expression in β-cells. Similarly,
SIRT1 is indeed an interesting target gene, however,
precautions should be taken in drug administration, diet
lifestyle, and targeted organs. Otherwise, the disruption
of the delicate balance of homeostasis may lead to
worsening physical conditions. Studying the SIRT1 sig-
nal transduction pathway and its effects on T2D in a
more long-term experiment will shed more under-
standing into how SIRT1 maintains homeostasis.
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